Log in to search using one of your social media accounts:

 

MD Anderson Study Shows Why Some Brain Cancers Resist Treatment
Scientists at The University of Texas MD Anderson Cancer Center may have discovered why some brain cancer patients develop resistance to standard treatments including radiation and the chemotherapy agent temozolomide. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - March 2, 2015 Category: Cancer & Oncology Source Type: news

No Benefit from Dose-Dense Chemo in Glioblastoma
(MedPage Today) -- Intensified chemoradiation with temozolomide for newly diagnosed glioblastoma failed to improve survival or slow disease progression, according to results of a randomized trial. (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - October 13, 2013 Category: Psychiatry Source Type: news

Migration capacity of human umbilical cord mesenchymal stem cells towards glioma in vivo
Glioblastoma is the most common ma-lignant primary brain tumor in adults. The aggressive growth manner, characterized by marked angiogenesis and extensive tumor cell invasion into normal brain parenchyma with frequent formation of tumor microsatellites at distal sites, makes eradication impossible even after extensive microsurgical resection combined with current standard chemoradiation and adjuvant temozolomide. Thus, novel therapeutic strategies must to be investigated for the development of a more effective treatment strategy... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 13, 2013 Category: Consumer Health News Tags: Stem Cell Research Source Type: news

Migration capacity of human umbilical cord mesenchymal stem cells towards glioma in vivo
(Neural Regeneration Research) Glioblastoma is the most common malignant primary brain tumor in adults. The aggressive growth manner, characterized by marked angiogenesis and extensive tumor cell invasion into normal brain parenchyma with frequent formation of tumor microsatellites at distal sites, makes eradication impossible even after extensive microsurgical resection combined with current standard chemoradiation and adjuvant temozolomide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2013 Category: Global & Universal Source Type: news

Researchers Aiming To Suppress Therapy Resistance In Brain Cancer
Gliomas are malignant brain tumors that arise from glial cells called astrocytes, found in the central nervous system. "In treating malignant gliomas, we currently combine radiotherapy with the anticancer drug temozolomide. However, in some patients, tumors rapidly become resistant to both treatment methods," says neurooncologist Professor Dr. Michael Platten, who leads a cooperation unit of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Department of Neurooncology of Heidelberg University Hospital... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 29, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Virus Combination Effective Against Deadly Brain Tumor, Moffitt Cancer Center Study Shows
A combination of the myxoma virus and the immune suppressant rapamycin can kill glioblastoma multiforme, the most common and deadliest malignant brain tumor, according to Moffitt Cancer Center research. Peter A. Forsyth, M.D., of Moffitt's Neuro-Oncology Program, says the combination has been shown to infect and kill both brain cancer stem cells and differentiated compartments of glioblastoma multiforme. The finding means that barriers to treating the disease, such as resistance to the drug temozolomide, may be overcome... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 24, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Roche's Avastin approved in Japan for treatment of the most aggressive form of brain cancer
Roche today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Avastin (bevacizumab) for the treatment of malignant glioma, including newly diagnosed glioblastoma (GBM) in combination with radiotherapy and temozolomide chemotherapy, and as monotherapy for treatment of recurrent GBM and certain other types of high grade glioma following prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - June 17, 2013 Category: Pharmaceuticals Source Type: news

Roche's Avastin approved in Japan for treatment of the most aggressive form of brain cancer
Roche today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Avastin (bevacizumab) for the treatment of malignant glioma, including newly diagnosed glioblastoma (GBM) in combination with radiotherapy and temozolomide chemotherapy, and as monotherapy for treatment of recurrent GBM and certain other types of high grade glioma following prior therapy. (Source: Roche Media News)
Source: Roche Media News - June 17, 2013 Category: Pharmaceuticals Source Type: news

Identifying Glioblastoma Patients Most Likely To Benefit From Bevacizumab
This study is associated with RTOG 0825, a large multi-center Phase III trial that evaluated the addition of bevacizumab to standard chemoradiation and maintenance temozolomide in treating newly diagnosed glioblastoma... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 4, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Roche announces final phase III study results of Avastin plus radiotherapy and chemotherapy in people with an aggressive form of brain cancer
Roche today announced final results from the phase III AVAglio study in people with newly diagnosed glioblastoma, the most common and aggressive form of primary brain cancer. Final results confirmed people who received Avastin (bevacizumab) plus radiotherapy and temozolomide chemotherapy benefited from a significant improvement in progression-free survival (PFS) compared to those who received placebo plus radiotherapy and temozolomide chemotherapy. Overall survival (OS) was not significantly improved in the study. (Source: Roche Investor Update)
Source: Roche Investor Update - June 1, 2013 Category: Pharmaceuticals Source Type: news

Roche announces final phase III study results of Avastin plus radiotherapy and chemotherapy in people with an aggressive form of brain cancer
Roche today announced final results from the phase III AVAglio study in people with newly diagnosed glioblastoma, the most common and aggressive form of primary brain cancer. Final results confirmed people who received Avastin (bevacizumab) plus radiotherapy and temozolomide chemotherapy benefited from a significant improvement in progression-free survival (PFS) compared to those who received placebo plus radiotherapy and temozolomide chemotherapy. (Source: Roche Media News)
Source: Roche Media News - June 1, 2013 Category: Pharmaceuticals Source Type: news

Best Treatment For High-Risk Low-Grade Glioma Is Still Radiotherapy
In a large, international, randomized trial, initial radiotherapy was compared to temozolomide chemotherapy. A statistically significant difference between the two treatment strategies was not observed for progression-free survival, although radiotherapy was numerically favored. However, molecular tumor characterization may allow the treatment approach to be personalized and one or the other treatment modality to be selected... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 31, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Radiotherapy remains the treatment of first choice for high-risk low-grade glioma
(European Organisation for Research and Treatment of Cancer) In a large, international, randomized trial, initial radiotherapy was compared to temozolomide chemotherapy. A statistically significant difference between the two treatment strategies was not observed for progression-free survival, although radiotherapy was numerically favored. However, molecular tumor characterization may allow the treatment approach to be personalized and one or the other treatment modality to be selected. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 29, 2013 Category: Global & Universal Source Type: news

Horizon scanning: Phase III Trial investigating cilengitide fails to meet primary endpoint of increasing overall survival in patients with newly diagnosed glioblastoma
Source: PharmaLive Area: News According to a report by PharmaLive, a phase III trial investigating cilengitide for newly diagnosed glioblastoma has failed to meet the primary endpoint, of increasing overall survival.   The phase III trial CENTRIC, was a randomised, controlled, multi-centre open-label trial which evaluated the safety and efficacy of cilengitide in combination with temozolomide and radiotherapy in more than 500 patients with newly diagnosed glioblastoma and methylated MGMT gene promoter status. (Source: NeLM - News)
Source: NeLM - News - February 26, 2013 Category: Drugs & Pharmacology Source Type: news

Cilengitide fails to meet primary endpoint in patients with newly diagnosed glioblastoma
Merck Serono, a division of Merck, Darmstadt, Germany, has announced that the Phase III CENTRIC trial of the investigational integrin inhibitor cilengitide did not meet its primary endpoint of significantly increasing overall survival when added to the current standard chemoradiotherapy regimen (temozolomide and radiotherapy). (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 25, 2013 Category: Drugs & Pharmacology Source Type: news

RCT: Tremelimumab does not improve survival in advanced melanoma
Source: JCO Area: News The Journal of Clinical Oncology has featured a study evaluating the cytotoxic T lymphocyte-associated antigen-4-blocking monoclonal antibody tremelimumab compared with standard-of-care chemotherapy in patients with advanced melanoma.   The phase III trial involved 655 patients with treatment-naive, unresectable stage IIIc or IV melanoma who were randomised to receive tremelimumab (15 mg/kg once every 90 days) or physician's choice of standard-of-care chemotherapy (temozolomide or dacarbazine). Tumour responses were assessed every 90 days (one cycle) in patients treated with tremelimumab, e...
Source: NeLM - News - January 8, 2013 Category: Drugs & Pharmacology Source Type: news